Obesity Causes Over 4 Million Deaths Per Year: Safe, Non-Invasive Treatments Could Help End Epidemic


Obesity Causes Over 4 Million Deaths Per Year: Safe, Non-Invasive Treatments Could Help End Epidemic

According to a new study published in the Endocrine Society’s journal, Endocrine Reviews, novel obesity treatments such as gut microbiota modification and gene therapy are underutilized and could help combat the obesity epidemic.

Obesity affects over half of adults and 20% of children in the United States, but doctors are under-prescribing effective weight-loss drugs, and many patients are not receiving the care they require. People with obesity are unwilling to seek care until comorbidities develop and reach a severe stage due to the weight stigma that occurs in healthcare settings. Obesity therapy is further hampered by a lack of insurance coverage and financial constraints.

“The epidemic crisis of our day is obesity.” “The condition causes substantial comorbidities including diabetes, fatty liver disease, and cardiovascular disease, as well as significantly reducing a person’s length and quality of life,” said Christos S. Mantzoros, M.D., Sc.D., of Boston’s Beth Israel Deaconess Medical Center. “We didn’t know the genetic and hormonal roots of obesity, or how obesity leads to various comorbidities, until recently.” We have only lately begun to comprehend the reasons of obesity in humans, which is a significant breakthrough that has led to the development of successful medicines.” The researchers outline the molecular and hormonal processes that contribute to obesity and its associated comorbidities in the publication. This information provides researchers with the information they need to develop, test, and implement new obesity treatments.

The researchers emphasize the need for more effective and safer obesity treatments, such as innovative medication delivery technologies, vaccinations, gut microbiota modification, and gene therapy. Novel drugs, such as combinations of gastrointestinal hormones and other compounds, are being studied and, once available, are likely to result in significant weight loss with fewer adverse effects. More effective treatments with fewer adverse effects will be developed as our understanding of obesity advances.

When paired with lifestyle adjustments, recently approved drugs such as semaglutide, a modified gastrointestinal hormone injected once a week, can result in a 15% weight loss. Although bariatric surgery can result in weight loss of up to 40%, it is intrusive and associated with problems.

“Insurance companies must pay attention to study findings and scientific development, and begin to cover treatments that are and will be available… Summary of the latest news from Brinkwire.


Comments are closed.